{"nctId":"NCT01041573","briefTitle":"Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population","startDateStruct":{"date":"2010-03"},"conditions":["Encephalitis"],"count":1869,"armGroups":[{"label":"IC51 0.5 mL","type":"EXPERIMENTAL","interventionNames":["Biological: IC51 Japanese Encephalitis"]},{"label":"IC51 0.25 mL","type":"EXPERIMENTAL","interventionNames":["Biological: IC51 Japanese Encephalitis"]},{"label":"Havrix 720","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Havrix®720"]},{"label":"Prevnar","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Prevnar"]}],"interventions":[{"name":"IC51 Japanese Encephalitis","otherNames":[]},{"name":"Havrix®720","otherNames":[]},{"name":"Prevnar","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female healthy children and adolescents aged \\> 2 months to \\< 18 years at the time of first vaccination.\n* Written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable.\n* Female subjects: either no childbearing potential or negative pregnancy test, for females after menarche willingness to practice a reliable method of contraception.\n\nExclusion Criteria:\n\n* Clinical manifestation of Japanese Encephalitis\n* History of Flavivirus vaccination (including any investigational vaccines)\n* History of vaccination with HAVRIX®720 and/or Prevnar®\n* History of immunodeficiency or immunosuppressive therapy\n* Known HIV, HBV or HCV infection\n* History of hypersensitivity reactions to other vaccines\n* Acute febrile infection at each visit during which the subject receives a vaccination\n* Active or passive immunization within 2 weeks prior to the first IC51 vaccination and up to the second IC51 vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination","description":"Rate of subjects with these types of AEs, comparison vs respective control vaccine stratified by age group: All study participants aged \\< 1 year: IC51 0.25mL vs. Prevnar; All study participants aged 1 year and above: IC51 0.25 mL or =.5 mL vs. Havrix.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"14.2","spread":null},{"groupId":"OG002","value":"38.2","spread":null},{"groupId":"OG003","value":"42.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMT) for JEV Neutralizing Antibodies","description":"GMT for JEV neutralizing antibodies is presented per dose group rather than age group due to overlapping age groups. IC51 0.25 mL includes subjects aged 2 months to \\< 12 years; IC51 0.5 mL includes subjects aged ≥ 3 years to \\< 18 years.","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":"1.802"},{"groupId":"OG001","value":"9.78","spread":"2.944"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199.39","spread":"3.387"},{"groupId":"OG001","value":"190.77","spread":"2.747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.99","spread":"3.267"},{"groupId":"OG001","value":"64.83","spread":"3.242"}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) at Days 0, 56 and at Month 7","description":"Seroconversion was defined as a PRNT50 titer of at least 1:10. SCRs are presented per dose group rather than age group due to overlapping age groups. IC51 0.25 mL includes subjects aged 2 months to \\< 12 years; IC51 0.5 mL includes subjects aged ≥ 3 years to \\< 18 years.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null},{"groupId":"OG001","value":"94.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With SAEs and Medically Attended AEs","description":"Rate of subjects with SAEs and medically attended AEs; For this analysis IC51 vaccine recipients are displayed by age group rather than by dose group. This allows comparison of the safety profile of IC51 with the active control for the respective age group: Prevnar for study participants aged \\>= 2 months to \\<1 year and Havrix 720 for study participants aged \\>= 1 year.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"14.2","spread":null},{"groupId":"OG002","value":"38.2","spread":null},{"groupId":"OG003","value":"42.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Solicited Local and Systemic AEs","description":"Rate of subjects with solicited local and systemic AEs. Solicited AEs of local and systemic tolerability, i.e., reactions at the injection site or systemic reactions typical for vaccinations, were to be evaluated for 7 consecutive days after each vaccination (except after the HAVRIX®750 and Prevnar® injections at Month 7 \\[Visit 4\\]) and recorded in the subject diary.\n\nFor this analysis IC51 vaccine recipients are displayed by age group rather than by dose group. This allows comparison of the safety profile of IC51 with the active control for the respective age group: Prevnar for study participants aged \\>= 2 months to \\<1 year and Havrix 720 for study participants aged \\>= 1 year.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"29.4","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"59.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7","description":"Rate of subjects with unsolicited AEs up to Day 56 and up to Month 7; For this analysis IC51 vaccine recipients are displayed by age group rather than by dose group. This allows comparison of the safety profile of IC51 with the active control for the respective age group: Prevnar for study participants aged \\>= 2 months to \\<1 year and Havrix 720 for study participants aged \\>= 1 year.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"72.5","spread":null},{"groupId":"OG003","value":"65.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null},{"groupId":"OG001","value":"57.6","spread":null},{"groupId":"OG002","value":"77.1","spread":null},{"groupId":"OG003","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Abnormal Laboratory Parameters","description":"Rate of subjects with abnormal laboratory parameters clinically significant results are shown below","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":871},"commonTop":["Upper Respiratory Tract Infection","Fever","Pyrexia","Redness","Nasopharyngitis"]}}}